New data from Jordan’s national surveillance suggests carbapenem resistance is widespread in Gram-negative ICU infections. The study reports that more than one in three Gram-negative infections in Jordanian intensive care units is resistant to carbapenems, pointing to a heavy burden in the setting where therapeutic options are often already constrained. Separately, a near-real-time Fluorescence PCR test can identify macrolide-resistant Mycoplasma pneumoniae in hours, potentially reducing the diagnostic lag that contributes to empiric treatment missteps. These two findings converge on a clinical operational issue: faster, more precise detection and better stewardship tools are becoming essential as resistance patterns intensify, especially in hospital-acquired environments.